The Claim
Daily supplementation with 45 μg of menaquinone-7 for 8 weeks reduces the undercarboxylated to carboxylated osteocalcin ratio by approximately 30% in healthy prepubertal children aged 6–10 years, without altering bone turnover markers or coagulation parameters.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In healthy children aged 6 to 10, taking 45 micrograms of vitamin K2 daily for 8 weeks lowers the ratio of inactive to active osteocalcin by about 30%, with no change in bone turnover or blood clotting markers.
See the scientific wording
Supplementation with 45 μg of menaquinone-7 (vitamin K2) daily for 8 weeks significantly reduces the undercarboxylated to carboxylated osteocalcin ratio (ucOC:cOC) by approximately 30% in healthy prepubertal children aged 6–10 years, indicating improved vitamin K status for bone protein activation, without altering bone turnover markers or coagulation parameters.
A vitamin K2 molecule enters the bloodstream from the gut, travels to bone cells, and helps an enzyme add a special chemical group to a bone protein. This change lets the protein bind to minerals in bone, making it functional. Without this vitamin, the protein stays inactive and cannot help build strong bone.
What the research says
1 studyGiving kids a daily vitamin K2 pill for two months helped their bodies activate a bone protein better, without changing how their blood clots or how their bones grow. The study proved it works.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.